Phaseline

Companies › Cho Pharma

Cho Pharma: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Vaccines, Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CHO-H01
Anti-CD20 monoclonal antibody
CD20Phase 1Non-Hodgkin LymphomaDec 2026
CHO-V08
Glycoconjugate bivalent vaccine against Klebsiella pneumoniae K1 and K2 serotypes
–Phase 1Klebsiella Pneumoniae InfectionApr 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05950165CHO-H01Phase 1Non-Hodgkin LymphomaOncologyDec 2026
NCT07016152CHO-V08Phase 1Klebsiella Pneumoniae InfectionVaccinesApr 2027

Targets

CD20 (1)

Companies with the same targets

AstraZeneca Johnson & Johnson (Janssen) Shanghai Jiaolian Drug Research and Development Lyell Immunopharma Zhejiang Teruisi Pharmaceutical AvenCell Therapeutics Adicet Therapeutics Cellectis Biocad Gilead Sciences

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.